Clifford Capital Partners LLC Buys 94,152 Shares of Pfizer Inc. (NYSE:PFE)

Clifford Capital Partners LLC raised its position in Pfizer Inc. (NYSE:PFE) by 21.3% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 536,745 shares of the biopharmaceutical company’s stock after acquiring an additional 94,152 shares during the period. Pfizer comprises approximately 3.3% of Clifford Capital Partners LLC’s holdings, making the stock its 13th largest holding. Clifford Capital Partners LLC’s holdings in Pfizer were worth $15,018,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the company. Olistico Wealth LLC bought a new position in Pfizer in the second quarter worth $25,000. MFA Wealth Advisors LLC bought a new stake in shares of Pfizer in the 2nd quarter valued at approximately $29,000. Quarry LP acquired a new position in shares of Pfizer in the 2nd quarter worth approximately $31,000. Creekmur Asset Management LLC bought a new position in shares of Pfizer during the 4th quarter worth approximately $32,000. Finally, Trivant Custom Portfolio Group LLC grew its position in Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $28.67 on Wednesday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $34.11. The stock has a market capitalization of $162.46 billion, a P/E ratio of -477.83, a P/E/G ratio of 1.27 and a beta of 0.68. The business has a 50-day moving average price of $29.28 and a two-hundred day moving average price of $28.31.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same period in the prior year, the business posted $0.67 earnings per share. Pfizer’s revenue was up 2.1% compared to the same quarter last year. Equities analysts predict that Pfizer Inc. will post 2.66 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have issued reports on PFE shares. UBS Group lifted their price objective on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Barclays boosted their price target on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Wells Fargo & Company raised their price objective on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a report on Monday, September 16th. Finally, Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and raised their price target for the company from $28.00 to $34.00 in a report on Wednesday, August 7th. Nine analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.